RecruitingNot ApplicableNCT02993029

99Tc-MDP Treatment for Knee Osteoarthritis

99Tc-MDP Versus Celecoxib Treatment in Patients With Knee Osteoarthritis

Sponsor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Enrollment

40 participants

Start Date

Sep 1, 2017

Study Type

INTERVENTIONAL

Conditions

Treatment Outcome

Summary

Osteoarthritis (OA) of knee is the most common form of arthritis in the world1e, and it has received growing attention in the society because of the increase of old age population, disabled people, and medical expenses from this disease. 99Tc-MDP is effective for rheumatoid arthritis. Therefore, the investigators try to investigate the effects of 99Tc-MDP treatment in patients with osteoarthritis of knee as compared with celecoxib.

Eligibility

Min Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called 99Tc-MDP and a drug called Celecoxib for people with treatment outcome. The study is currently recruiting participants at 1 location. People eligible for this study include aged 40 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG99Tc-MDP

99Tc-MDP 15mg in 100ml normal saline intravenously dripped every twice a week for 5 weeks, every 1weeks for 10 weeks, every 2weeks for 10 weeks, every 1 month for 6 months.

DRUGCelecoxib

Celecoxib capsule 200mg qd by mouth.